VBL Therapeutics Announces That S-4 Registration Statement For Proposed Merger With Notable Labs Is Declared Effective By SEC
Portfolio Pulse from Happy Mohamed
VBL Therapeutics (NASDAQ:VBLT) has announced that its S-4 registration statement for the proposed merger with Notable Labs has been declared effective by the SEC. The merger, announced on February 23, 2023, is expected to close in mid-October 2023, subject to shareholder approval. The combined organization plans to apply Notable's Predictive Precision Medicines Platform to develop a pipeline of clinical-stage precision medicines in oncology.
September 06, 2023 | 12:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
VBL Therapeutics' proposed merger with Notable Labs has been approved by the SEC, moving the merger process forward. The merger is expected to close in mid-October 2023, pending shareholder approval.
The SEC's approval of the S-4 registration statement is a significant step towards the completion of the merger between VBL Therapeutics and Notable Labs. This news is likely to be viewed positively by investors, as it indicates progress in the merger process. However, the final impact on VBLT's stock price will depend on shareholder approval of the merger, which is expected to be sought in mid-October 2023.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100